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Background: Opioid analgesics are the most effective drugs for the treatment of moderate to severe pain.
However, they also produce several adverse effects that can complicate pain management. The μ opioid (MOP)
receptor, a G protein-coupled receptor, is recognized as the opioid receptor type which primarily mediates the
pharmacological actions of clinically used opioid agonists. The morphinan class of analgesics including morphine
and oxycodone are of main importance as therapeutically valuable drugs. Though the natural alkaloid morphine
contains a C-6-hydroxyl group and the semisynthetic derivative oxycodone has a 6-carbonyl function, chemical
approaches have uncovered that functionalizing position 6 gives rise to a range of diverse activities. Hence, position
6 of N-methylmorphinans is one of the most manipulated sites, and is established to play a key role in ligand
binding at the MOP receptor, efficacy, signaling, and analgesic potency. We have earlier reported on a chemically
innovative modification in oxycodone resulting in novel morphinans with 6-acrylonitrile incorporated substructures.
Results: This study describes in vitro and in vivo pharmacological activities and signaling of new morphinans
substituted in position 6 with acrylonitrile and amido functions as potent agonists and antinociceptive agents
interacting with MOP receptors. We show that the presence of a 6-cyano group in N-methylmorphinans has a
strong influence on the binding to the opioid receptors and post-receptor signaling. One 6-cyano-N-methylmorphinan
of the series was identified as the highest affinity and most selective MOP agonist, and very potent in stimulating G
protein coupling and intracellular calcium release through the MOP receptor. In vivo, this MOP agonist showed to be
greatly effective against thermal and chemical nociception in mice with marked increased antinociceptive potency
than the lead molecule oxycodone.
Conclusion: Development of such novel chemotypes by targeting position 6 provides valuable insights on
ligand-receptor interaction and molecular mode of action, and may aid in identification of opioid therapeutics
with enhanced analgesic properties and fewer undesirable effects.
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Pain is a physiological integrated part of human life and
protects the body from any potentially dangerous ther-
mal, mechanical or chemical injury. This biological pro-
cess involves different regulation levels (peripheral, spinal,
supraspinal), where pain signals are transmitted and mo-
dified along the pain pathways, reaching the brain and
resulting in pain awareness [1]. Moreover, pain is a com-
plex multidimensional phenomenon, and its highly sub-
jective nature makes it difficult to define and to treat
clinically. Nowadays, effective pain management is still a
therapeutic priority, with pain being an incapacitating
symptom of many medical conditions [2,3].
Among the three opioid receptor types, μ (MOP), δ
(DOP) and κ (KOP), the MOP receptor is the main type
involved in modulation of pain perception, and it has
the most clinical value in pharmacotherapy of pain with
opioid analgesics [4]. Similar to the other two receptors,
DOP and KOP, the MOP receptor displays the topolo-
gy characteristics of the rhodopsin family of G protein-
coupled receptors (GPCRs) with seven transmembrane
loops [5], and is expressed at central and peripheral sites
within the pain control circuits. An important milestone
in the opioid field, represented by elucidation of the
MOP receptor structure, was recently reached [6].
Morphine (Figure 1) and all structurally related com-
monly used opioid analgesics for the treatment of mo-
derate to severe pain are agonists at the MOP receptor
[4,7]. Morphine has high effectiveness as an analgesic
drug and a long history of clinical use, in spite of its
serious side effects, such as constipation, respiratory de-
pression, sedation, nausea and vomiting [8]. Codeine (3-
O-methylmorphine, Figure 1) is used as analgesic for
mild to moderate pain, with 5 to 6 times less potency
than morphine [7]. The morphinan oxycodone (Figure 1)
is nowadays one of the most frequently used opioid anal-
gesics, with potency comparable to that of morphine [9].
A main problem associated with oxycodone is its highMorphine R1 = H
Codeine R1 = H
Oxycodone R1 = OH
14-OMC R1 = OCH3
Oxymorphone R1 = OH
14-OMO R1 = OCH3
Figure 1 Structures of morphine, codeine, oxycodone, 14-O-methylox
(14-OMO).abuse potential. 3-O-Demethylation of oxycodone leads
to an active metabolite, oxymorphone (Figure 1), a clin-
ically used analgesic, while also representing a valuable
scaffold for the development of new generations of li-
gands interacting with the MOP receptor [10-12]. Over
the years, intensive investigations have been directed to-
ward optimization of morphinan-6-ones, and significant
developments and the therapeutic potential of the gener-
ated molecules or their use as valuable research tools
have been reported. Our work in the 6-ketomorphinan
class of opioid analgesics has led to the design of 14-
alkoxy substituted morphinan-6-ones as MOP agonists
that are highly effective antinociceptive agents in various
experimental models of pain [10,11]. Replacement of
the hydroxyl group in position 14 of oxymorphone
with a methoxy group led to 14-O-methyloxymorphone
(Figure 1), which shows 9 times increased binding affinity
at the MOP receptor [13] and is up to 40 times more
potent in inducing an antinociceptive effect than oxy-
morphone in animals [14]. Furthermore, position 6 of
N-methylmorphinans has been extensively targeted, and
found to play a key role in ligand interaction with the
MOP receptor, and also analgesic properties. Medicinal
chemists have taken the synthetic approach of converting
the C-6 carbonyl group into various functionalities, lead-
ing to hydrazones, oximes, carbazones and semicarbazone
derivatives of N-methyl-6-ketomorphinans [15-18], where
high antinociceptive potency was combined with reduced
unwanted side effects like respiratory depression and gas-
trointestinal inhibition [19,20]. Zwitterionic molecules
with interesting pharmacological profiles were designed
through the introduction of 6 amino acid residues in 14-
alkoxymorphinans [21-27]. Such MOP receptor agonists
induce potent and long-lasting peripherally mediated an-
tinociceptive actions after systemic subcutaneous (s.c.)
administration. Recently, we have reported on the de-
velopment of 14-O-methyloxymorphone derivatives with
an amino and guanidino group in position 6 [28]. TheseR2 = OH R3 = α-OH, Δ7,8
R2 = OCH3 R3 = α-OH, Δ7,8
R2 = OCH3 R3 = O
R2 = OCH3 R3 = O
R2 = OH R3 = O
R2 = OH R3 = O
ycodone (14-OMC), oxymorphone and 14-O-methyloxymorphone
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vity and efficacy, and were very active as antinocicep-
tive agents.
Another synthetic strategy to convert the carbonyl
group of morphinan-6-ones was described by the replace-
ment of the 6-keto group with an acrylonitrile substi-
tution to provide the N-methylmorphinans 1–3 (Figure 2)
[29,30], without major alterations in the opioid activities
in vitro and in vivo compared to their 6-keto analogues
[30]. The resulted compounds exhibited high affinity at
the MOP receptor, MOP selectivity and antinociceptive
potencies [30]. However, the presence in positions 4 or
14 of a methoxy instead of a hydroxyl group in the 6-
cyanomorphinans affects the interaction with opioid re-
ceptors, by increasing affinity and selectivity for the MOP
receptor, together with augmenting antinociceptive po-
tencies [30]. With the aim of extending structure-activity
relationships (SAR) in this class of compounds, further 6-
acrylonitrile incorporated N-methylmorphinans (5 and 6)
and the corresponding amido derivative 4 have been syn-
thesized [31] (Figure 2). The present study was under-
taken to evaluate their in vitro biological properties
(opioid receptor binding and functional activities), and
in vivo behavioral properties (nociception), in comparison
to the previously reported analogues 1–3, and the lead
molecule oxycodone. While no data have been reported
on the effect of 6-cyanomorphinans 1–3 on G protein
coupling or second messenger signaling, herein we de-
scribe the in vitro characterization of compounds 1–6 in
terms of their agonist potency and efficacy to induce
MOP receptor-mediated G protein signaling (guanosine-
5′-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) binding)
and mobilization of intracellular calcium (calcium fluor-
escence measurements). The present studies were also
conducted to evaluate the antinociceptive activities of
the new derivatives 4–6 in tests of thermal (hot-plate
and tail-flick tests) and chemical (paraphenylquinone
(PPQ) abdominal stretching assay) sensitivity. All these
investigations may provide further information on key
structural features at position 6 in N-methylmorphinans1 R1 = H R2 = H R3 = 
2 R1 = H R2 = CH3 R3 = 
3 R1 = CH3 R2 = H R3 = 
4 R1 = CH3 R2 = CH3 R3 = 
5 R1 = CH3 R2 = CH3 R3 = 
Figure 2 Structures of N-methylmorphinans 1–6.that influence affinity, selectivity, efficacy and potency
at the MOP receptor.
Results
Opioid receptor binding affinity and selectivity
Binding affinities at MOP, DOP and KOP receptors of
the new 6-acrylonitrile incorporated N-methylmorphi-
nans (5 and 6) and the corresponding amido derivative
4 were determined by radioligand binding assays in rat
brain membranes. Data as inhibition constant (Ki) values
and selectivity ratios are listed in Table 1. For compari-
son purposes, opioid binding affinity data for the previ-
ously reported 6-cyanomorphinans 1–3 and oxycodone
are included. Compared to the lead molecule oxycodone,
all three new derivatives 4–6 displayed a marked in-
crease in MOP receptor affinity. As shown in Table 1,
compounds 4–6 bound with high affinity at the MOP
receptor, with derivative 5 having a Ki value of 0.54 nM
in the rat brain, paralleled by the highest MOP receptor
selectivity. All three compounds had one to two orders
of magnitude lower affinities at DOP and KOP recep-
tors. The 6-amido substituted derivative 4 also showed
high MOP receptor affinity in the low nanomolar range
(Ki value of 1.61 nM)), but reduced MOP selectivity. The
presence of a 6-cyano group in 5 appears to be favorable
for both affinity and selectivity for the MOP receptor,
while a 6-amido substitution (4) leads to 3 to 9 times
lower MOP receptor affinity, and up to 5 and 7 times re-
duced MOP receptor selectivity vs. DOP and KOP re-
ceptors, respectively. In addition, the high affinity at the
MOP receptor displayed by the 6-cyanomorphinan 5 in
the rat brain was also demonstrated at the recombinant
rat MOP receptor expressed in C6 glioma cells (C6rMOP,
Ki = 0.70 nM). In line with findings in the rat brain, low
binding affinities were determined for this compound in
C6 cells transfected with rat DOP receptors (C6rDOP,
Ki = 56 nM) and Chinese hamster ovary (CHO) expres-
sing human KOP receptors (CHOhKOP, Ki = 229 nM),
thus extending the outcomes on the high MOP selecti-
vity of 5 (80 times vs. DOP and 327 times vs. KOP).CN 6
CN
CN
CONH2
CN, Δ7,8
Table 1 Binding affinities and selectivities at MOP, DOP
and KOP receptors
Ki (nM)
a Selectivity ratios
MOP DOP KOP DOP/
MOP
KOP/
MOP
Oxycodoneb 43.6 ± 1.5 1,087 ± 246 2,658 ± 367 25 61
14-OMC 35.3 ± 2.1 116 ± 15 454 ± 6 3 13
1b 31.7 ± 2.1 498 ± 79 1,648 ± 201 16 52
2b 2.44 ± 0.13 107 ± 5 364 ± 7 44 149
3b 5.38 ± 0.42 197 ± 29 378 ± 155 37 70
4 1.61 ± 0.05 28.8 ± 2.3 105 ± 45 18 65
5 0.54 ± 0.04 30.3 ± 2.9 200 ± 40 56 370
6 7.39 ± 0.34 239 ± 40 194 ± 68 32 26
aMembranes from rat brain were used. bData from [30]. Values represent the
mean ± SEM of at least three experiments each performed in duplicate.
Table 2 Agonist activities at the MOP receptor
[35S]GTPγS functional
assaya
Calcium mobilization
assayb
EC50 (nM) Emax (%)
c EC50 (nM) Emax (%)
c
Oxycodone 500 ± 128 92 ± 9 1,176 ± 347 38 ± 3
14-OMC 325 ± 94 137 ± 55 973 ± 204 72 ± 7
1 273 ± 24 98 ± 4 957 ± 233 57 ± 4
2 42.5 ± 14.9 97 ± 15 116 ± 9 69 ± 7
3 26.2 ± 1.7 85 ± 3 140 ± 21 61 ± 6
4 25.6 ± 9.5 107 ± 26 56.1 ± 11.3 59 ± 8
5 1.64 ± 0.19 133 ± 7 21.7 ± 5.5 70 ± 8
6 25.1 ± 3.6 121 ± 27 173 ± 21 84 ± 10
DAMGO 20.2 ± 5.6 100 42.7 ± 7.6 100
aMembranes from CHO cells stably transfected with human MOP receptors
were used. bCHO cells co-expressing Gαqi5 protein and recombinant human
MOP receptor were used. cEmax is expressed in percentage relative to maximal
DAMGO induced stimulation in each assay (225 ± 32% and 217 ± 21% in
[35S]GTPγS functional and calcium mobilization assay, respectively, set as
100%). Values represent the mean ± SEM of at least three experiments each
performed in duplicate or triplicate.
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bridged 6 to the earlier developed non-bridged analogue
3 depicted no major changes in the MOP affinity and
selectivity. It was also noted that methylation of the 4-
hydroxy group in compounds 2, 4 and 5 gives rise to an
improved interaction with the MOP receptor. When
compared the 14-methoxy and 6-cyano substituted 6 to
its 6-keto counterpart 14-O-methyloxycodone (14-OMC),
it was observed that the presence of a 6-acrylonitrile
moiety increases binding to the MOP receptor by about 5
times (Table 1). Also, a similar increase was observed in
the case of the other two new 14-methoxy substituted de-
rivatives 4 and 5. The presence of a hydroxyl group in
both 4 and 14 positions (compound 1) appears to largely
affect binding at the MOP receptor. Compared to 6-
cyano-N-methylmorphinans 1–3 described earlier [30],
the new analogues 4 and 5 had one order of magnitude
lower Ki values at the DOP receptor, with the 6-cyano
derivative 6 showing comparable and reduced affinity.
Also, like the 6-cyanomorphinans 1–3, compounds 4–
6 retained the decreased binding at the KOP receptor
(Table 1).
Functional activity
Compounds 1–6, oxycodone and 14-OMC were exam-
ined for their agonist potencies and efficacies at the
MOP receptor. Stimulation of [35S]GTPγS binding and
intracellular calcium release were determined and com-
pared to the effect exerted by the reference MOP re-
ceptor agonist DAMGO (Table 2). First, we investigated
the effects of the N-methylmorphinans 1–6 at the level
of MOP receptor-mediated G protein signaling using
agonist-stimulated [35S]GTPγS binding in membranes
from CHO cells expressing human MOP receptors
(CHOhMOP). In CHOhMOP cell membranes, all investi-
gated opioid ligands produced concentration-dependent
increase in [35S]GTPγS binding (Figure 3A). Resultsshowed that the 6-cyano substituted 2, 3, 5 and 6, and their
amido analogue 4 had one order of magnitude higher po-
tency based on the EC50 values than oxycodone and 14-
OMC, while the 4,14-dihydroxy-6-cyanomorphinan 1 dis-
played comparable potency (Table 2). Derivative 5 was the
most potent agonist with an EC50 value of 1.64 nM, a
profile equivalent to the one observed in the radioligand
binding studies (Table 1). The new 6-cyanomorphinan 5
proved also to be more potent than DAMGO (EC50 =
20.2 nM) in stimulating G protein signaling, while the
analogues 1–4 showed similar or lower potencies. The
6-amido substituted 4 had an about 16 times higher
EC50 value compared to its 6-cyano analogue 5, but
similar potency to the other two 6-cyanomorphinans 2,
3 and 6. The 4-methoxy analogue 2 had an about 6
times greater potency than its 4-hydroxy counterpart 1.
A further increase in potency resulted upon methylation
of the hydroxyl group in position 14, leading to compound
3 with about 10 times lower EC50 value than its analogue
1. The 6-cyanomorphinans 1–6 were full agonists, and
showed similar efficacies to oxycodone for G protein
coupling (Table 2, Figure 3A).
We have further assessed the ability of the investigated
compounds to activate second messenger systems cou-
pled to the calcium mobilization pathway. Changes in
intracellular calcium concentration were determined in
CHOhMOP cells expressing the Gαqi5 chimeric protein
using a whole cell fluorescence-based assay. All com-
pounds evoked a concentration-dependent stimulation
of calcium release (Figure 3B). As shown in Table 2, over-
all the rank order of potencies of compounds 1–6 in
stimulating calcium release is largely in agreement with
the [35S]GTPγS findings, with compound 5 being the
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Figure 3 In vitro agonist activities at the MOP receptor of compounds 1–6, oxycodone and 14-OMC. Concentration-response curves in (A)
[35S]GTPγS functional assay with membranes from CHO expressing human MOP receptors and (B) calcium mobilization experiments performed
with CHO cells co-expressing the human MOP receptor and the Gαqi5 protein. Activity is calculated as percentage of maximal DAMGO stimulation
in each assay (225 ± 32% and 217 ± 21% in [35S]GTPγS functional and calcium mobilization assay, respectively, set as 100%). Calculated potencies
and efficacies are presented in Table 2. Data are shown as the mean ± SEM (n≥ 3).
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of 21.7 and 56.1 nM, respectively). The other 6-cyano
substituted derivatives 1, 2, 3 and 6 exhibited up to 10
times greater potency than oxycodone and 14-OMC.
Compared to DAMGO (EC50 = 42.7 nM), the new 6-
cyano substituted 5 was about 2 times more potent, and
the other derivatives had EC50 values ranging from 56.1
to 957 nM. Generally, the EC50 values calculated in the
calcium mobilization assays were one order of magni-
tude higher than those determined in the [35S]GTPγS
binding assay. Also, some differences in compounds effi-
cacies were noticed between the two assays, where largely
lower relative efficacies compared to DAMGO were found
regarding intracellular calcium release in CHOhMOP cells.
All derivatives 1–6 and 14-OMC showed greater efficacies
than that of oxycodone (Table 2, Figure 3B).
Antinociceptive effects
The new derivatives 4–6 were evaluated in vivo for their
antinociceptive effects in mice after s.c. administration
using three well-established and commonly used tests,
hot-plate, tail-flick and PPQ abdominal stretching. Both0
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Figure 4 Dose-dependent antinociceptive effects produced by compo
test. (C) PPQ abdominal stretching test. Hot-plate and tail-flick latencies (as
determined as described in Materials and Methods. Data are shown as thehot-plate and tail-flick assays are valuable models for
acute thermal nociception. Activity in the hot-plate test
suggests that a drug acts at the supraspinal level, whereas
the tail-flick may reflect spinal activity [32]. The PPQ
assay evaluates chemical sensitivity, and is established as a
model for visceral pain [32]. Dose-dependent antinocicep-
tive effects are illustrated in Figure 4. Antinociceptive po-
tencies expressed as ED50 values are listed in Table 3, and
were compared with those of the previously reported
N-methyl-6-cyanomorphinans 1–3 [30], oxycodone and
14-OMC.
As shown in Table 3, compounds 4–6 produced po-
tent antinociceptive effects in all three in vivo assays.
The 6-cyano substituted 5 and 6 exhibited markedly
higher antinociceptive potencies than the 6-amido
analogue 4, and were up to 165 times more active than
oxycodone. The 6-acrylonitrile 4,5-oxygen bridged 6
showed comparable potency to its analogue 5 in the
hot-plate and PPQ tests, and it was 3 times less potent
in the tail-flick test. Compared to the earlier described
derivatives 1–3 [30], the new 6-cyanomorphinans 5 and
6 were overall more potent as antinociceptive agents in0
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unds 1–6, oxycodone and 14-OMC. (A) Hot-plate test. (B) Tail-flick
% MPE) and PPQ-induced stretching response (as % inhibition) were
mean ± SEM (n = 6–10 mice per group).
Table 3 Antinociceptive activities
ED50 (mg/kg, s.c.) (95% CL)
HPa TFb PPQc
Oxycodoned 1.37 (0.48-3.92) 0.94 (0.40-2.30) 0.38 (0.19-0.75)
14-OMC 1.02 (0.52-2.01) 0.80 (0.32-2.04) 0.22 (0.12-0.41)
1d 0.50 (0.12-2.02) 1.88 (1.25-2.83) 0.18 (0.076-0.42)
2d 0.15 (0.054-0.41) 0.12 (0.061-0.23) 0.026 (0.012-0.055)
3d 0.25 (0.11-0.59) 0.21 (0.11-0.40) 0.11 (0.072-0.16)
4 1.30 (0.56-3.03) 1.34 (0.53-3.03) 0.18 (0.08-0.43)
5 0.080 (0.011-0.61) 0.040 (0.020-0.090) 0.0023 (0.0009-0.0060)
6 0.089 (0.037-0.21) 0.12 (0.070-0.20) 0.003 (0.0007-0.012)
Antinociceptive potencies in mice after s.c. administration shown as ED50 values with 95% confidence limits (95% CL) (n = 6–10 mice per group).
aHot-plate (HP)
test. bTail-flick (TF) test. cPPQ abdominal stretching test. dData from [30].
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against thermal and chemical nociception. The 6-amido
derivative 4 was as potent as compound 1 in the tail-
flick and PPQ assays, while it was about 3 times less
active in the hot-plate test (Table 3). Antinociceptive po-
tencies of compound 4 were also found to be compar-
able to those of 14-OMC and oxycodone. The 14-
methoxy-6-cyanomorphinan 6 was 11, 7, and 72 times
more potent than its 6-keto counterpart 14-OMC in in-
ducing an antinociceptive response in the hot-plate, tail-
flick, and PPQ assays, respectively. In addition to antino-
ciception, MOP agonists are well-recognized to elicit
other behavioral changes in rodents. In the current
study, there were no sedative effects observed at any of
the tested doses. Some increase in locomotor activity
was noticed in mice, however, this only occurred at
doses in the upper end of the dose–response curve, i.e.
90% of analgesia. Further investigations will be needed
to establish the side effect profile of these opioids.
Discussion
Though natural opioid alkaloids such as morphine and
codeine (Figure 1) contain a 6-hydroxyl group, synthetic
approaches have uncovered that functionalizing position
6 gives rise to a wide range of diverse activities [28].
Thus, position 6 of the morphinan skeleton has been a
major target for successful drug developments over the
years, leading to various opioid agonists and antagonists
that are of importance both for clinical use and research.
Oxycodone and oxymorphone (Figure 1), clinically used
as opioid analgesics, are two representative examples of
structural variation at C-6, where a carbonyl instead of a
hydroxyl group is present in position 6. By targeting the
chemically highly versatile 6-keto function of morphinan-
6-ones as in oxycodone, we have previously reported on a
chemically innovative modification giving rise to a novel
class of morphinans with acrylonitrile incorporated sub-
structures [29,30]. The resulted acrylonitrile incorpo-
rated 4,5-oxygen bridge-opened N-methylmorphinans(1–3, Figure 1) emerged as high affinity and potent MOP
antinociceptive agents, with a pharmacological profile
comparable to that of their 6-keto counterparts [30]. The
interesting approach to incorporate acrylonitrile substruc-
tures into morphinans was further explored by our group
and resulted in new derivatives [31].
In the present study, combining in vitro ligand binding
and functional assays and in vivo behavioral approaches,
we show that the presence of a cyano group in position
6 in N-methylmorphinans has a strong influence on opi-
oid receptor binding and post-receptor molecular events.
In line with our previous findings, having a 6-cyano
group in N-methylmorphinans (5 and 6) results in in-
creased MOP receptor activity compared to the lead
molecule oxycodone both in vitro and in vivo. In the
series of 6-cyanomorphinans, the new derivative 5 was
consistently identified to exhibit the highest affinity and
selectivity at the MOP receptor and to be the most po-
tent MOP agonist. The design of compound 5 having a
4,14-dimethoxy substitution was attained based on our
earlier observations, when a 4-methoxy group and/or a
14-methoxy group, like in compounds 2 and 3, is more
favorable for binding and selectivity for the MOP recep-
tor and antinociceptive activity than the corresponding
hydroxy counterpart 1 [30]. Herein, we also establish that
the presence of a methoxy group in both positions, 4 and
14, has a major impact not only on binding affinities to all
three opioid receptor types, and MOP receptor select-
ivity, but also on agonist potencies and efficacies at
this receptor.
We have also examined how the combination of a C-6
cyano functionality together with a closed 4,5-oxygen
bridge (compound 6) will affect in vitro and in vivo opi-
oid activities. The two 6-cyanomorphinans 3 and 6 show
high and similar affinities at the MOP receptor, and low
binding to DOP and KOP receptors. In both functional
studies, [35S]GTPγS binding and intracellular calcium
mobilization, compounds 3 and 6 acted as potent MOP
agonists with comparable EC50 values, and a somewhat
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cyanomorphinan 6 with a closed 4,5-oxygen bridge was
more potent than its 4,5-oxygen bridge-opened analogue
3 in inducing an antinociceptive effect in mice after s.c.
administration (ca. 3 times in the hot-plate, 2 times in
the tail-flick and 37 times in the PPQ tests). Closing of
the 4,5-oxygen bridge in the 6-acrylonitrile substituted 3
produces no major changes in interaction with the MOP
receptor in vitro, but augmented antinociceptive potency.
On the other hand, the 14-methoxy-6-cyanomorphinan 6
showed greater MOP receptor affinity and agonist potency
than 14-OMC and the 14-hydroxy substituted oxycodone,
together with much better antinociceptive properties.
It was of interest to assess the result of the conversion
of the 6-acrylonitrile to a 6-amido group on the inter-
action with opioid receptors, signaling, and the link be-
tween antinociceptive efficacy and the mode of action.
Since the presence of 4- and 14-methoxy groups was fa-
vorable in the case of the 6-cyano substituted N-methyl-
morphinan 5, the same substitution pattern was applied
to the 6-amido analogue 4. It was remarkable to note
that the presence of an amido group in position 6 resulted
in high affinity at the MOP receptor and also good MOP
selectivity. In the [35S]GTPγS functional assay, the 6-
amido substituted 4,5-oxygen bridge-opened 4 acted as a
highly efficacious agonist at the MOP receptor with sev-
eral times increased potency than oxycodone, 14-OMC
and 4,14-dihydroxy substituted 6-cyanomorphinan 1. The
same profile was depicted for compound 4 when stimulat-
ing G protein signaling and intracellular calcium release
through MOP receptors. When compared to the 6-cyano
analogue 5, the 6-amido group in 4 appears to largely
affect agonist potency, leading to reduced activity, espe-
cially in antinociceptive potency. It is possible that differ-
ential metabolism of derivatives 4 and 5 may determine
the differences in the in vivo activity. Primary aliphatic
amides are known to be rapidly metabolically hydrolyzed
[33], whilst the nitrile group is more stable [34].
In this study, we described the in vitro functional
activities of the previously reported 6-cyanomorphinans
1–3 and oxycodone based on the assessment of MOP
receptor-mediated G protein activation and intracellular
calcium mobilization. Replacement of the 4-hydroxy
group in 6-cyanomorphinan 1 with a 4-methoxy group
in analogue 2, or substitution of 14-hydroxyl in com-
pound 1 with a 14-methoxy group in 3 results in 6 to 10
times enhanced agonist potencies and comparable effica-
cies, upon the test being used. Compared to the 6-
ketomorphinans oxycodone and 14-OMC, the 6-cyano
substituted N-methylmorphinans 1–3 generally displayed
higher agonist activity in vitro, which correlates well with
the in vivo results on antinociceptive properties. Among
all investigated N-methylmorphinans, derivative 5 is
the most potent agonist in terms of G protein couplingand changes in intracellular calcium concentration.
This MOP agonist potency enhancement of the new
6-cyanomorphinan 5 compared to the other deriva-
tives established in the two functional assays is in
agreement with the outcomes from in vitro binding
assays and nociceptive tests, and supports the import-
ance of the presence of both methoxy groups in positions
4 and 14 in this class of opioid morphinans [30].
The clinically relevant analgesic oxycodone was found
as the MOP ligand with the lowest agonist potency in
the series of the investigated morphinans. In CHOhMOP
cell membranes, oxycodone stimulated [35S]GTPγS
binding with a EC50 value of 500 nM, which is lower
than the EC50 value of 1.40 μM reported by Thompson
et al. in the same cell line [35]. In the same work, a
lower relative efficacy as percentage stimulation com-
pared to DAMGO at the human MOP receptor in CHO
cells was found for oxycodone (67%), while in our study
a higher efficacy, i.e. 92% stimulation relative to DAMGO,
was determined (Table 2). Comparable potency (EC50 =
373 nM) and lower relative efficacy (66%) for oxycodone
to our data was reported in C6rMOP cells [36]. Similarly, in
CHOhMOP cells stably expressing the Gαqi5 chimeric pro-
tein, oxycodone exhibited low activity, by producing
stimulation of calcium release with an EC50 value of 1,176
nM and an efficacy of 38%. A recent study [37] reported
on changes in intracellular calcium levels produced by
oxycodone in human embryonic kidney-293 (HEK293)
cells co-expressing the human MOP receptor and Gαqi3
chimeric protein, with low potency (1.74 μM) and high ef-
ficacy (100%). Although 14-OMC also displays low agonist
potencies at the human MOP receptor in both functional
systems, it shows a similar efficacy compared to oxyco-
done in [35S]GTPγS binding and in calcium mobilization,
that is also seen in antinociceptive potency. Mostly, com-
pounds 1–6, oxycodone and 14-OMC were found to be
more potent MOP agonists in the terms of G protein acti-
vation based on the lower EC50 values by one order of
magnitude than the EC50 values for the calcium signaling,
and with lesser efficacies measured in the latter. Presum-
ably these differences may be due to variances in receptor
reserve in the two cell lines, and/or possibly membranes
vs. intact cells. Differences in signaling may also be regu-
lated by the MOP receptor localization within the plasma
membrane [38,39]. Receptor localization within the lipid
rafts after agonist binding can promote G protein coupling
or recruitment of other intracellular regulatory proteins
[40,41]. Over the past years, increased attention has been
drawn to the understanding of intracellular signaling path-
ways that mediate the therapeutic and/or adverse effects
of opioid agonists acting at the MOP receptor [42-44].
In vitro and in vivo studies demonstrate that different
opioids can initiate distinct cellular and physiological re-
sponses downstream of receptor activation [40,42]. The
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tions not only of the type and structure of the agonist
acting at the receptor but also of the cellular environ-
ment in which the receptor is expressed [40]. Moreover,
the present understanding of MOP receptor function is
persistently increasing, as the crystal structure is now
available [6].Conclusions
In summary, the present study explored in vitro and
in vivo pharmacological activities and signaling of new
morphinans substituted in position 6 with acrylonitrile
and amido functions as potent agonists and antinocicep-
tives interacting with the MOP receptor. Particularly,
the 3,4,14-trimethoxy substituted 6-cyano-N-methylmor-
phinan 5 was identified as the most efficacious MOP
agonist of the series, and future studies remain to ana-
lyze in more detail pathway-dependent agonist efficacy
and signaling, and the side effect profile. Development
of novel chemotypes as highly active and selective MOP
agonists through targeting position 6 in N-methylmor-
phinans provide important insights into ligand-receptor
interaction, and thereby better understanding of the lin-
kage between analgesic efficacy and molecular mode of
action. The advances in SAR illustrated in this study
serve as a valuable tool for designing molecules with op-
timal configuration that may aid in identification of opi-
oid therapeutics with more favorable pharmacological
features, powerful analgesia and less undesirable effects.Materials and methods
Materials
Opioid radioligands [3H][D-Ala2,Me-Phe4,Gly-ol5]enke
phalin ([3H]DAMGO), [3H]5α,7α,8β-(−)N-methyl-N-
[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl]benzeneace-
tamide ([3H]U69,593) and [35S]GTPγS were purchased
from PerkinElmer (Boston, USA). [3H][Ile5,6]deltorphin
II was obtained from the Institute of Isotopes Co. Ltd.
(Budapest, Hungary). DAMGO, naloxone, tris(hydroxy-
methyl)aminomethane (Tris), 2-[4-(2-hydroxyethyl)piper-
azin-1-yl]ethanesulfonic acid (HEPES), unlabeled GTPγS,
guanosine diphosphate (GDP) were obtained from Sigma-
Aldrich Chemicals (St. Louis, MO, USA). All cell culture
media and supplements were from Sigma-Aldrich Chemi-
cals (St. Louis, MO, USA) and Invitrogen (Paisley, UK).
Oxycodone was prepared as described [31]. 14-OMC
was prepared according to procedures earlier described
[45]. Compounds 1–3 were prepared according to the
published procedures [29,30]. Derivatives 4–6 were syn-
thesized as described [31]. All other chemicals were of
analytical grade and obtained from standard commercial
sources.In vitro assays
Radioligand binding assays
Binding assays were performed as described previously
using rat brain membranes [22], and membranes from
C6 glioma cells stably expressing the rat MOP receptor
(C6rMOP) or the rat DOP receptor (C6rDOP), and from
CHO cells stably expressing the human KOP receptor
(CHOhKOP) [36]. Protein concentration was determined
by the Bradford method using bovine serum albumin as
the standard [46].
Membranes were prepared from Sprague–Dawley rat
brains obtained from the Institut für Labortierkunde und
Laborgenetik, Medizinische Universität Wien (Himberg,
Austria). Binding experiments were performed as in
50 mM Tris–HCl buffer (pH 7.4) in a final volume of
1 ml containing 300–500 μg protein [22]. Rat brain
membranes were incubated either with [3H]DAMGO
(1 nM, 45 min, 35°C), [3H][Ile5,6]deltorphin II (0.5 nM,
45 min, 35°C) or [3H]U69,593 (1 nM, 30 min, 30°C) and
different concentrations of the test compound. Non-
specific binding was determined in the presence of
10 μM naloxone. Reactions were terminated by rapid
filtration using a Brandel Cell Harvester (Brandel Inc.,
Gaithersburg, MD) and Whatman GF/B glass fiber filters
pre-soaked in 0.1% polyethylenimine for 1 h at 4°C for
[3H]U69,593, or type GF/C for [3H]DAMGO and [3H]
[Ile5,6]deltorphin II. Filters were washed three times with
5 ml of ice-cold 50 mM Tris–HCl buffer (pH 7.4) and
bound radioactivity was measured by liquid scintillation
counting.
C6rMOP cells and C6rDOP cells [47], and CHOhKOP cells
[48] were grown to confluence, and used in ligand bind-
ing assays. C6 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing fetal bovine serum
(FBS, 10%), under 5% CO2 in the presence of geneticin
(0.25 mg/ml). CHO cells were maintained in DMEM/
Ham F-12 medium containing FBS (10%), under 5% CO2
in the presence of geneticin (0.25 mg/ml). Cell membranes
(25 μg) were incubated with 0.2 nM [3H]diprenorphine
and different concentrations of the test ligand in 50 mM
Tris–HCl buffer, pH 7.4, for 90 min at 25°C in a final vol-
ume of 1 ml. Nonspecific binding was defined with 10 μM
naloxone. Samples were filtered through glass fiber filters
(45 μm; Schleicher & Schuell, Keene, NH) mounted in a
Brandel Cell Harvester (Brandel Inc., Gaithersburg, MD)
and rinsed three times with ice-cold 50 mM Tris–HCl
buffer pH 7.4. Radioactivity retained on the filters was
counted by liquid scintillation counting. All binding exper-
iments were performed in duplicate and repeated at least
three times.
[35S]GTPγS functional assays
CHO cells expressing recombinant human MOP receptors
(CHOhMOP) were grown in DMEM/Ham F-12 medium
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(0.1%), L-glutamine (2 mM) and geneticin (400 μg/ml)
[49]. Cell cultures were maintained at 37°C in 5% CO2
humidified air. Membranes were prepared in buffer A
(20 mM HEPES, 10 mM MgCl2 and 100 mM NaCl,
pH 7.4) as described [27]. Cell membranes (5 μg) were in-
cubated with 0.05 nM [35S]GTPγS, 10 μM GDP and dif-
ferent concentrations of the test compound for 60 min at
25°C, in a total volume of 1 ml. Nonspecific binding was
determined using 10 μM GTPγS, and the basal binding
was assessed in the absence of test ligand. Samples were
filtered over Whatman GF/B glass fiber filters and counted
as described for binding assays. All experiments were per-
formed in triplicate and repeated at least three times.
Calcium mobilization assays
CHOhMOP stably expressing the C-terminally modified
Gαqi5 were cultured in DMEM/Ham F-12 containing FBS
(10%), penicillin (100 IU/ml), streptomycin (100 mg/ml),
L-glutamine (2 mM) geneticin (200 μg/ml) and hygromy-
cin B (100 μg/ml). Cell cultures kept at 37°C in 5% CO2 in
humidified air were used in the calcium mobilization as-
says performed as described previously [50]. Cells were
seeded at a density of 50,000 cells per well into 96-well
black, clear-bottom plates. After 24 h, the cells were loa-
ded with medium supplemented with 2.5 mM probenecid,
3 μM of the calcium sensitive fluorescent dye Fluo-4 AM
and 0.01% pluronic acid, for 30 min at 37°C. The loading
solution was replaced by Hank’s Balanced Salt Solution
(HBSS) supplemented with 20 mM HEPES, 2.5 mM pro-
benecid and 500 μM Brilliant Black, for 10 min at 37°C.
After placing both plates (cell culture and compound
plate) into the FlexStation II (Molecular Device, Union
City, CA), fluorescence changes were recorded. All experi-
ments were performed in duplicate and repeated at least
three times.
In vivo assays
Animals
ICR male mice (Harlan-Sprague–Dawley, Indianapolis,
IN) weighing 20–30 g were used. All procedures involv-
ing animals were carried out in accordance to the Guide
for the Care and Use of Laboratory Animals, U.S. De-
partment of Health and Human Services, 1985, and
were approved by the Institutional Animal Care and
Use Committee at Virginia Commonwealth University.
Drugs were given by s.c. route. At least three doses were
tested, and 6–10 animals per dose were used.
Hot-plate test
The hot-plate test was performed in mice using a modi-
fied procedure [51] of the earlier described method [52].
Each mouse was exposed to the hot plate (Thermojust
Apparatus, Richmond, VA) maintained at 56°C for twotrials spaced 5 min apart. Only mice that gave control
response latency in the range of 6–10 s on both trials
were used. Each mouse received a dose of test drug or
vehicle and 30 min later was again tested on the hot
plate. Activity was scored as positive if the mouse jumped,
licked, or shook its paws at least 5 s beyond its average
control latency. Cut-off time was set at 15 s. Percent
activity for each dose tested was calculated as (total
number of mice scored as positive)/(total number of
mice tested) × 100.Tail-flick test
The tail-flick test was performed according to the ori-
ginal procedure described [53] and with some modifica-
tions as reported [51]. The mouse’s tail was placed in a
groove, which contained a slit under which was located
a photoelectric cell. Mice were injected with test drug or
vehicle and tested 20 min later. Antinociception was cal-
culated as% MPE (percent maximal possible effect) =
(test latency – control latency)/(10 s – control latency) ×
100 for each dose tested. A 10 s cut-off was imposed to
minimize tissue damage.PPQ abdominal stretching test
The procedure for the PPQ test was described previously
[51,54]. Mice were injected with the test drug or vehicle
10 min prior receiving intraperitoneally (i.p.) 2 mg/kg of
a freshly prepared PPQ solution. Mice were then placed
in three cages in groups of two each. The total number
of stretches observed per group during each 1 min per-
iod was counted at 10 and 15 min. The total number of
stretches for the three groups was determined. A stretch
was characterized by an elongation of the mouse’s body,
development of tension in the abdominal muscles and
extension of the hind limbs. The antinociceptive response
was expressed as percentage (%) inhibition of the PPQ-
induced stretching response and was calculated as [1 –
(total number of stretches in the medicated mice)/(total
number of stretches in the control mice)] × 100.Data analysis
Binding and functional data were analyzed with the
GraphPad Prism software (GraphPad Software Inc., San
Diego, CA). Concentration-response curves were cons-
tructed and inhibition constant (Ki, nM), agonist potency
(EC50, nM) and efficacy (Emax, as percentage of maximum
stimulation with respect to the reference MOP agonist
DAMGO) were calculated using nonlinear curve fitting
analysis. Data are represented as the mean ± SEM. For
in vivo assays, the effective dose ED50 and 95% confidence
limits (95% CL) were calculated using the method of
Litchfield and Wilcoxon, 1949 [55].
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